News
2 mars 2023
Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn’s disease patients stopping infliximab.
Read more
A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.
“A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial”, Radford-Smith D.E., Satsangi J., Louis E., Laharie D., Ding Siegmund B., D’Haens G., Hertervig E., Yates A., Anthony D.C., Colombel J.F., Probert F., GETAID and the SPARE-Biocycle research group., Journal of Crohn’s and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i458–i460, https://doi.org/10.1093/ecco-jcc/jjab232.621.
For more information, please visit the BIOCYCLE project website at https://biocycle-project.eu/ EU reference: grant agreement No 633168 – BIOCYCLE (PHC-13-2014).